Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Study Identifier
M02-518
CT.gov Identifier
NCT00646386
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Rheumatoid Arthritis
  • Psoriatic Arthritis (PsA)
    • Study Drug
  • adalimumab
  • placebo for adalimumab
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Moderate to severe PsA - Inadequate response to DMARD therapy - Corticosteroid stable dose <= 10 mg QD - DMARDs must have been taken for 3 months and stable dose for 4 weeks - MTX maximum dose = <= 30 mg/week - Active chronic plaque PS or documented history of chronic plaque PS
    Exclusion Criteria:
    - No other active skin disease

    Protocol Summary

    Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody

    Adalimumab in Subjects with Moderately to Severely Active Psoriatic Arthritis

    Study Locations

    No locations found.